How to access Ctexli for cerebrotendinous xanthomatosis from the UAE: 2026 pathway via CCAD and Tawam metabolic-genetics programmes | Reserve Meds
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
The UAE diagnoses CTX through paediatric and adult neurology referrals at Cleveland Clinic Abu Dhabi (CCAD) and Tawam Hospital, with additional cases captured at Burjeel Medical City and Mediclinic City Hospital Dubai. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement therapy for CTX, given that EDE has not yet domestically registered the product.
Ask about Ctexli in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Why Ctexli, why now
Ctexli (chenodiol, chenodeoxycholic acid) received US FDA approval in February 2024 as the first labelled treatment for cerebrotendinous xanthomatosis (CTX) in adult and paediatric patients. Mirum Pharmaceuticals is the US sponsor. CTX is a rare autosomal recessive bile-acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, the gene encoding sterol 27-hydroxylase. The enzyme deficiency disrupts bile-acid synthesis and leads to accumulation of cholestanol and bile alcohols in tissues. Untreated CTX manifests with chronic diarrhoea, juvenile cataracts, tendon xanthomas, premature atherosclerosis, and progressive neurologic deterioration including cerebellar ataxia, pyramidal signs, dystonia, peripheral neuropathy, psychiatric features, and cognitive decline. Most patients develop neurologic symptoms in the second or third decade if untreated.
The 2026 question for a UAE patient with CTX is how to source Ctexli now that there is finally a labelled treatment. With FDA approval less than 24 months ago, Ctexli is not yet registered with the Emirates Drug Establishment (EDE), so the UAE pathway is named-patient personal-import authorisation under EDE's personal-medication framework.
What Ctexli is, in plain language
Ctexli is an oral chenodiol capsule. Mechanistically it replaces the bile acid (chenodeoxycholic acid) the patient's deficient enzyme cannot produce and restores feedback suppression of the upstream cholesterol-to-bile-acid pathway, lowering accumulated cholestanol. Ctexli does not reverse pre-existing neurologic damage. It slows or halts progression, with strongest benefit when initiated before significant neurologic deterioration. Dosing is weight-based, given orally three times daily with food, lifelong.
Access pathway in the UAE
The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance for the UAE. The Department of Health Abu Dhabi (DoH Abu Dhabi), the Dubai Health Authority (DHA), and MOHAP for the Northern Emirates govern healthcare facility licensing. Ctexli is not currently EDE-registered. Access runs through an EDE-approved named-patient personal-import authorisation, with the relevant emirate-level health authority acknowledgment, filed by the treating clinician at CCAD, Tawam, SKMC, Burjeel Medical City, Mediclinic City Hospital Dubai, American Hospital Dubai, or one of the other licensed specialty centres. The UAE diagnoses CTX through paediatric and adult neurology referrals at Cleveland Clinic Abu Dhabi (CCAD) and Tawam Hospital, with additional cases captured at Burjeel Medical City and Mediclinic City Hospital Dubai.
The treating neurologist or metabolic specialist submits the named-patient import application documenting the biallelic CYP27A1 confirmation, elevated plasma cholestanol, neurological status, and requested dose and supply quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Ctexli from a US DSCSA-compliant specialty wholesaler or an EU-licensed supplier and arranges shipping to Abu Dhabi or Dubai International Airport.
Eligibility at a UAE metabolic-genetics or neurology clinic
Ctexli eligibility requires biallelic pathogenic variants in CYP27A1 on molecular genetic testing plus elevated plasma cholestanol (typically more than five-fold above the upper limit of normal). The CCAD genetic disease programme and Tawam paediatric neurology each handle confirmation. Paediatric cases are managed in paediatric neurology at CCAD, Tawam, or via cross-border referral to Sidra Medicine Qatar; adult cases run through adult neurology at CCAD, SKMC, or the Dubai-based centres. The treating clinician documents baseline neurological examination, MRI white-matter findings, baseline liver function, and any systemic features (tendon xanthomas, juvenile cataracts, chronic diarrhoea, premature atherosclerosis, psychiatric features).
Documentation required
The patient and physician should be prepared to provide: a current Emirates ID or passport; the molecular genetic report confirming biallelic CYP27A1 variants; recent plasma cholestanol levels; baseline neurological examination notes; recent brain MRI (with attention to dentate nucleus and white-matter signal); recent liver function tests; documentation of prior empiric chenodeoxycholic acid use, if any; the treating physician's prescription on hospital letterhead; the clinical justification letter; the EDE named-patient import application; the emirate-level health authority acknowledgment (DoH Abu Dhabi, DHA, or MOHAP); and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US or EU export documentation, manufacturer pedigree, and customs packet.
Costs and funding considerations
Medicine price: quote on request. You get a written quote for your case before you commit. Pre-approval, CTX patients in the region were typically maintained on compounded chenodeoxycholic acid. Thiqa coverage for Emirati nationals may apply under the rare-disease provision case-by-case. DHA Saada for Emirati nationals in Dubai applies similarly. Daman Enhanced, AXA Gulf, Allianz, MetLife, and BUPA Arabia plans typically require pre-authorisation with the genetics report and a treating-specialist letter; coverage for an unregistered ultra-orphan agent is unusual but not impossible. Reserve Meds will help structure the insurer or government-payor submission.
Typical timeline
Weeks 0 to 4: confirm diagnosis, prescription preparation, EDE import filing through the UAE hospital pharmacy. Weeks 4 to 8: shipment arrival at Abu Dhabi or Dubai International Airport, initiation under metabolic-clinic supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, and tolerability monitoring. Months 6 and 12: full metabolic and neurologic reassessment, repeat plasma cholestanol, and brain MRI white-matter assessment.
When Ctexli is the wrong drug
Without biallelic CYP27A1 pathogenic variants, the diagnosis is not CTX and Ctexli is not indicated. Normal plasma cholestanol calls the CTX diagnosis into question; pursue alternative metabolic and neurogenetic workup. Advanced neurologic damage in untreated patients means the realistic goal is stabilisation rather than reversal; family counselling should reflect this. Pregnancy data are limited; contraception is required for women of childbearing potential. Significant hepatic dysfunction requires careful dose adjustment.
Frequently asked questions
- Is the pathway legal in the UAE? Yes. It operates under EDE named-patient personal-import authorisation with emirate-level health authority acknowledgment under federal UAE medicines law.
- Will Thiqa, DHA Saada, or my insurance cover Ctexli? Emirati nationals may secure Thiqa or DHA Saada rare-disease case-by-case support; private insurance coverage for ultra-orphan agents is unusual but pre-authorisation with documented genetics is the path to attempt.
- How long does treatment continue? Lifelong. CTX is a chronic genetic disease.
- Can I use generic chenodeoxycholic acid instead? Empirically yes in some jurisdictions; however, Ctexli is the FDA-approved labelled product with quality and supply assurance. The treating clinician decides.
- What if Ctexli is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
- Can my child be treated? Yes; Ctexli is FDA-approved for paediatric patients. Paediatric cases in the UAE are typically managed at CCAD, Tawam paediatric neurology, or via cross-border Sidra confirmation.
Closing
Reserve Meds runs the Ctexli supply file from CCAD or Tawam metabolic-genetics referral through EDE named-patient authorisation, US or EU sourcing, and delivered supply. Clinical decisions remain with your treating metabolic specialist or neurologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will send a written quote for your case.
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist or neurologist.
Reviewed by the Reserve Meds clinical operations team. We use AI tools to help draft and check content.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Ctexli in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Ctexli for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ctexli in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ctexli. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ctexli in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ctexli to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ctexli to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Ctexli in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ctexli in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.